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Elevation of cerebral Mg2+with a novel orally delivered ionophore, magnesium threonate, enhances cognition
in young and old rats over a 12-24 day treatment interval, as outlined in a paper by Slutsky et al. in this issue of
Neuron. Despite both Mg2+ and Zn2+ blocking the NMDA receptor channel, sustained extracellular Mg2+
elevation mimics sustained synaptic Zn2+ concentrations by increasing hippocampal NR2B expression
and bouton density.Since Otto Loewy remarked ‘‘Ja Kalzium,
das ist alles!’’ in 1959, calcium developed
an almost unassailable status as the
predominant inorganic metal ion for its
diverse roles in biochemistry and, of
course, neurochemistry (Carafoli, 2002).
But in the last 10 years a steadily
increasing amount of research has high-
lighted the importance of the other bioi-
norganic metal ions in functional neuro-
chemistry. In this issue of Neuron,
Slutsky et al. (2010) present compelling
data that an oral agent that delivers
magnesium (Mg) to the brain improves
cognition in young and old rats. These
findings carry several important implica-
tions, not the least of which is that oral
agents that target the inorganic milieu of
the brain can markedly impact cognitive
function and its biochemical substrates.
Mg supplementation has been previ-
ously reported to enhance cognitive
performance in young and old rats (Land-
field and Morgan, 1984), but, as Slutsky
et al. point out, oral Mg supplementation
is not efficiently bioavailable, and the
large doses of Mg2+ required to benefit
the animals lead to gastrointestinal side
effects that limit the translatability of the
benefits. Slutsky et al. successfully over-
came this problem by identifying a Mg2+
ionophore, threonate, that forms a stable
complex with Mg (MgT) with much better
orally bioavailability than Mg2+ salts. The
blood-brain barrier (BBB) is remarkably
impervious to plasma metal ion fluctua-
tions so that brain tissue is protected
from the dramatic changes in metal ion
levels that occur with prandial status.
The authors point out that even a sus-
tained elevation in plasma Mg2+ by infu-
sion with MgSO4 causes only a modest
elevation in CSF Mg in humans, and nochange in brain Mg in rats. Therefore,
they searched for a chaperone or iono-
phore to try to overcome the BBB imper-
meability. Following oral treatment with
Mg-equivalent doses of MgT, MgCl2,
and magnesium-gluconate, only MgT
induced an elevation in CSF Mg levels
after 24 days. Even then the increase in
CSF Mg was only modest (15%), but there
was no increase at all with the other
supplements. The elevation of CSF Mg
induced by MgT may actually reflect
a much larger Mg increase in the cortical
parenchyma or synapses, because Mg2+
may enter the CSF from the brain tissue
(Hallak et al., 1992).
Because Mg2+ blocks the NMDA
receptor (NMDAR) channel opening,
elevating extracellular Mg2+ might have
been expected to inhibit cognition.
However, the authors had built their
hypothesis also upon their previous
observations that increasing extracellular
Mg2+ concentrations 50% within the
physiological range for protracted (4 hr)
periods in primary neuronal cultures
causes permanent enhancement of
synaptic plasticity despite blocking Ca2+
flux through the NMDAR channel (Slutsky
et al., 2004). In the current manuscript, the
group extends their in vitro examination of
the sustained elevation of extracellular
Mg2+ by extensive electrophysiological
studies in primary neuronal cells and
hippocampal slices. The slices were
treated for 5 hr with 50% elevated Mg2+
(1.2 mM), which, the authors show, leads
to an increase in the number of functional
presynaptic release sites with lower
release probability. To summarize the
in vitro studies, sustained elevation of
extracellular Mg2+ does not merely block
the NMDAR, but acts also as a firstNeuron 65messenger to induce adaptation of the
synapse in a manner that facilitates LTP:
despite the block, an apparent upregula-
tion of the NMDAR leads to NMDAR
background currents remaining constant,
but with enhanced current during bursting
activity.
The authors argue that that this mecha-
nism could underlie the impressive array
of cognitive benefits that follow treat-
ment with MgT for 12–30 days. Young
(2-month-old) and old (18- to 22- month-
old) MgT-treated rats demonstrated
significantly improved performance in
this time frame in the novel object re-
cognition test (short-term memory), the
T-maze test (spatial working memory),
and the Morris water maze (spatial long-
term memory, and memory recall). Curi-
ously, while the improvement in T-maze
performance was sustained in the young
rats for 5 weeks after MgT treatment, the
performance of old treated rats rapidly
deteriorated but could be revived with a
second treatment. This could reflect an
age-dependent inability to maintain
a reservoir of brain Mg. While this storage
lesion is still unknown, its importance is
underscored by the prevalence of Mg defi-
ciency in old age that the authors note.
Consistent with the increase in func-
tional release sites found in neurons and
slices treated with sustained elevations
of extracellular Mg2+, MgT-treated rats
had significantly increased densities of
hippocampal presynaptic boutons, and
the increase correlated with improved
memory performance. The authors link
this to a 60% elevation in hippocampal
NR2B (but not NR2A or NR1) and BDNF
(+36%) levels in MgT-treated animals.
This is reminiscent of our own recent find-
ings that hippocampal NR2B levels also, January 28, 2010 ª2010 Elsevier Inc. 143
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extracellular Zn2+, the other extracellular
metal ion that blocks the NMDAR
channel. ZnT3 knockout mice, which
lose the release of presynaptic Zn2+
upon activation at glutamatergic
synapses, exhibit decreases in NR2B
(50%), pro-BDNF (30%), and the
density of hippocampal boutons (Adlard
et al., 2010). Therefore, NR2B expression
may be regulated by factors that block the
channel. Notably, however, Mg2+ and
Zn2+ bind at different sites of the channel,
but the physiological significance is
unclear (Mony et al., 2009).
Like any good paper, this report opens
many questions. The caveat acknowl-
edged by the authors is the proposed
mechanism of action of MgT. While the
in vitro data on the proposed adaptive
mechanism is attractive, its premise is
that extracellular Mg2+ elevations are sus-
tained, and there is no direct evidence of
that, only the modest rise (7%–15%) in
CSF Mg, which does not reach the 50%
level of the in vitro studies. In vivo micro-
dialysis measurements may help defend
the proposed model of action. Also, there
is an intracellular Mg2+ store that seems to
fatigue with aging, yet it could also repre-
sent a site of action of MgT that cannot be
excluded from the data.
Considering that intravenous Mg2+ has
been in existence as a treatment for pre-
eclamptic seizures for decades (Euser
and Cipolla, 2009), and that evidence
supports its use in preventing damage of
the BBB (e.g., in stroke), it is remarkable
how little is known about the mechanism
of Mg2+ transport across the BBB. Poten-
tial mechanisms of action of Mg2+ in these
clinical situations include stabilization of
the BBB and increased perfusion, which
may also contribute to the benefits of
MgT in the current report. Yet, Mg2+ is144 Neuron 65, January 28, 2010 ª2010 Elsenot a wonder drug for brain injury. A
recent large phase 2 clinical trial for
head injury found that moderate intrave-
nous Mg2+ treatment significantly wors-
ened outcome (Temkin et al., 2007).
MgT, nevertheless, represents a very
promising lead for drug development,
and shows that the BBB can be pharma-
cologically surmounted to therapeutically
increase the uptake of metal ions by
the brain. This is also the principal of
recent Alzheimer’s disease (AD) candi-
date disease-modifying ionophore com-
pounds clioquinol and PBT2, which facili-
tate the uptake of Zn2+ and Cu2+ captured
from amyloid pathology into cortical
parenchymal cells (Adlard et al., 2008).
PBT2 showed beneficial effects in a recent
phase 2 clinical trial in AD (Lannfelt et al.,
2008). Therefore, the medical chemistry
of brain interstitial metal ion concentra-
tions seems to be rapidly developing as
a promising avenue of potential interven-
tion for cognitive disorders.
It should be interesting to test MgT in
models of neurological injury wherein
Mg2+ has been implicated, such as
stroke, head-injury, epilepsy, AD, and
Parkinson’s disease. One issue facing
the planning of potential clinical trials is
the large dose that was effective in the
current studies: 604 mg/kg/d (50 mg eq
Mg). Even when allowing for a body
surface area correction when translating
(Reagan-Shaw et al., 2008), the estimated
human dose for early phase trials would
be 98 mg/kg/d or about 7 g of MgT per
day, which could be an impractical dose
for a trial. However, this work should
spur the exploration of further novel
Mg2+ ionophores or organic chaperones.
In any case, work like this enhances the
appreciation of the inorganic milieu of
the brain beyond the preoccupation with
calcium. Hence, ‘‘Kalzium ist nicht alles.’’vier Inc.ACKNOWLEDGMENTS
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